Seegene, Samsung Enter Cancer MDx Pact | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Seegene and Samsung Medical Center today said they will collaborate to develop new molecular diagnostics tests directed at cancer.

The partnership combines Seegene's MDx technology with Samsung's clinical and disease pathology expertise, the two firms said. They added that Samsung will provide the first test sites for the diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.